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Objective: The heterogeneous nature of mesenchymal stem cells (MSCs) and the absence of known MSC-
speciﬁc biomarkers make it challenging to deﬁne MSC phenotypes and characteristics. In this study, we
compared the phenotypic and functional features of human placenta-derived MSCs with those of human
dermal ﬁbroblasts in vitro in order to identify a biomarker that can be used to increase the purity of MSCs
in a primary culture of placenta-derived cells.
Materials and methods: Liquid chromatography-tandem mass spectrometry analysis was used to analyze
and compare the proteome of human placenta-derived MSCs with that of ﬁbroblasts. Quantitative real-
time polymerase chain reaction, immunoﬂuorescence, and ﬂow cytometry were used to determine
expression levels of EphA2 in placenta-derived MSCs. EphA2-positive cells were enriched by magnetic-
activated cell sorting or with a cell sorter. An shRNA-mediated EphA2 knockdown was used to assess the
role of EphA2 in MSC response to Tumor necrosis factor (TNF)-a stimulation.
Results: Analysis of proteomics data fromMSCs and ﬁbroblasts resulted in the identiﬁcation of the EphA2
surface protein biomarker, which could reliably distinguish MSCs from ﬁbroblasts. EphA2 was signiﬁ-
cantly upregulated in placenta-derived MSCs when compared to ﬁbroblasts. EphA2 played an important
role in MSC migration in response to inﬂammatory stimuli, such as TNF-a. EphA2-enriched MSCs were
also more responsive to inﬂammatory stimuli in vitrowhen compared to unsorted MSCs, indicating a role
for EphA2 in the immunomodulatory functionality of MSCs.
Conclusion: EphA2 can be used to distinguish and isolate MSCs from a primary culture of placenta-
derived cells. EphA2-sorted MSCs exhibited superior responsiveness to TNF-a signaling in an inﬂam-
matory environment compared with unsorted MSCs or MSC-like cells.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.arch Department, Meridigen
d, Neihu District, Taipei City
t of Obstetrics and Gynecol-
Road, Xindian District, New
.-W. Teng), yogi@meridigen.
bstetrics & Gynecology. PublishedIntroduction
Mesenchymal stem or stromal cells (MSCs), which are multi-
potent cells of embryonic mesodermal origin, have a ﬁbroblast-like
morphology. Depending on the stimuli and culture conditions,
these cells can differentiate into adipocytes, osteocytes, chon-
drocytes, neural lineage cells, or myocytes among other cell types.
Although the plasticity of human MSCs (hMSCs) and their role in
tissue repair and regeneration have been extensively studied, there
has been a recent focus on their immunological trophic properties
[1,2]. hMSCs have been isolated from a variety of tissues, with theby Elsevier Taiwan LLC. All rights reserved.
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However, the procedure to isolate MSCs from bone marrow is
extremely invasive. Tissues, such as human umbilical cord and
placenta, which are normally discarded after labor, have been
considered as attractive alternative sources for noninvasive isola-
tion of hMSCs, and previous studies have reported efﬁcient isola-
tion of hMSCs from umbilical cord or placenta [3].
MSCs represent a more complex stromal cell subpopulation
contained in mesenchymal tissue. Due to the heterogeneous na-
ture of MSCs and the absence of known MSC-speciﬁc biomarkers,
it is a challenging task to deﬁne MSC phenotypes and character-
istics [4e6]. The molecular components responsible for MSC
functionalities, particularly those on the plasma membrane,
remain largely unknown. Additionally, lack of speciﬁc cell-surface
markers increases the risk of contamination of MSC cell cultures
with other cell types, speciﬁcally mature stromal cells, such as
ﬁbroblasts, which are abundant in mesenchymal tissue [4e6].
Isolation of MSCs from placenta-derived tissues is complicated by
the fact that non-MSCs, such as ﬁbroblasts, placenta-derived
epithelial cells, and placenta-derived reticular cells, often coexist
with MSCs. Fibroblasts, in particular, are the main source of
contamination.
Fibroblasts are considered mature mesenchymal cells that are
particularly abundant in the connective tissue, and are conse-
quently the most frequent contaminating-cell phenotype in many
cell-culture systems. Not only is it difﬁcult to successfully eliminate
ﬁbroblasts from a culture, it is also particularly complex to distin-
guish MSCs from ﬁbroblasts in the same culture. Fibroblasts and
MSCs have a similar morphological appearance; they both prolif-
erate well and have many identical cell-surface markers [7,8]. MSCs
are currently deﬁned by the International Society of Cellular
Therapy as plastic adherent, multipotent, ﬁbroblast-like cells
expressing CD73, CD105, and negative for the hematopoietic
markers CD14, CD34, and CD45. However, since these properties
and markers are also shared by ﬁbroblasts, the current deﬁnition
fails to distinguish MSCs from generic ﬁbroblasts. Currently, the
best way to distinguishMSCs from ﬁbroblasts is based on functional
properties; MSCs retain multipotent stemness and immunomo-
dulation capacity, while ﬁbroblasts seem more limited in both of
these functional areas.
Since Friedenstein et al's [9] pioneering work on identiﬁcation
of MSCs, there have been no reports on distinct differences in
culture-derivation methodology, morphology, or gene expression
signatures that would consistently and unequivocally distinguish
ex vivo culture-expanded MSCs from ﬁbroblasts [10e13]. There is
currently also no accepted criterion or single cell-surface marker
that can be used for separating MSCs from ﬁbroblasts. Due to the
fact that the ﬁbroblast is the most common contaminant in MSC
cultures derived from the placenta, it is crucial to identify a novel
surface protein that can be used as a biomarker to distinguish MSCs
from ﬁbroblasts in order to ensure the homogeneity of primary
cultures of placenta-derived MSCs.
Human erythropoietin-producing hepatocellular (Eph) receptors
include transmembrane proteins comprising the largest family of
receptor tyrosine kinases. The ﬁrst identiﬁed function of Eph re-
ceptors was their role in the complicated and sophisticated mech-
anism underlying axon guidance. Eph receptors are now known to
regulate a wide range of cell-to-cell communication events involved
in cell positioning and tissue patterning during embryonic devel-
opment. They also play a role in the pathology of cancer and vascular
complications [14e18]. Additionally, these receptors are important
regulators of specialized cell functions involved in synaptic plas-
ticity, insulin secretion, bone remodeling, epithelial homeostasis, as
well as inﬂammatory and immune responses [14,15,19]. They are
expressed by a wide variety of cell types, such as neurons, vascularcells, epithelial cells, inﬂammatory cells, immune cells, and tumor
cells, including cancer stem cells [20e23].
The EphA2 gene belongs to the Eph-receptor subfamily of the
protein-tyrosine kinase family. EphA2 has previously been shown
to play a role inmediating developmental events, particularly in the
nervous system. EphA2 functions in speciﬁc aspects of pattern
formation during development and subsequently in the develop-
ment of several fetal tissues. It is involved in vasculogenesis, neural
tube development, axial mesoderm formation, early hindbrain
development, neuron differentiation, regulation of cell migration,
bone remodeling through regulation of osteoclastogenesis and
osteoblastogenesis, mammary gland epithelial-cell proliferation,
and branching morphogenesis during mammary gland develop-
ment [24]. In particular, the role of EphA2 in nervous system em-
bryonic development is well-deﬁned [25], and it has been
implicated in the process bywhich neurons send out axons to reach
the correct targets.
Recent studies reported the role of Eph receptors in stem-cell
biology, both during embryonic development and in adult stem
cells. Eph receptors are expressed in most adult stem-cell niches.
Stem cells are located in specialized microenvironments, or niches,
deﬁned as the combination of cellular and microenvironmental
determinants orchestrating the self-renewal and differentiation of
stem-cell pools within specialized tissue locations. The expression
of Eph receptors and ephrin ligands during embryogenesis and tis-
sue homeostasis is consistent with their involvement in stem-cell
regulation during development and in adult tissue homeostasis
[26,27]. It has been suggested that the Eph/ephrin system has a
spatiotemporal regulatory function in the balance between stem-
cell quiescence, self-renewal, and differentiation [28]. However,
the mechanism by which Eph is involved in maintenance of the
stem-cell niche and its role in stem-cell regulation are not well
understood. EphA2 is highly expressed in embryonic stem cells [29].
Quantitative proteomics studies showing high expression of EphA2
in human bone marrow MSCs and human umbilical cord peri-
vascular cells (HUCPVCs) conﬁrmed that it is upregulated in
mesenchymal progenitor populations [30]. Nevertheless, the ma-
jority of the EphA2 functional studies in stem cells have been
focused on the nervous system. EphA2 is highly expressed in the
central nervous system, including precursors in neuronal and glial
lineages [25,27]. Recent studies provided evidence that ephrin-A1
promotes the motility of EphA2-positive cardiac stem cells, result-
ing in enhanced regeneration and cardiac function after myocardial
infarction [31]. Besides these ﬁndings, the expression proﬁle and
functions of EphA2 in stem-cell science are not yet well understood.
In this study, we compared the phenotypic and functional fea-
tures of humanplacenta-derivedMSCswith those of normal human
dermal ﬁbroblasts in vitro. Our proteomics data showed that
expression of the EphA2 surface-speciﬁc marker can be used to
distinguishMSCs in a primaryculture of cells derived fromplacenta-
related tissue. Our study provides a method of increasing the purity
of the MSC population in a primary culture of cells derived from
placenta-related tissue, based on the expression level of EphA2.
Additionally, in vitro functional assays showed that the EphA2-
enriched MSC population was responsive to tumor necrosis factor
(TNF)-a-dependent signaling in an inﬂammatory environment.
Materials and methods
Isolation of MSCs from placenta and umbilical cord
Placental tissues were collected from healthy full-term placenta
(n ¼ 8). Written informed consent was obtained from individual
mothers before the study, which was approved by the Ethics
Committee of the Cardinal Tien Hospital. The age range of the
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4C until placement in a biological safety cabinet. Placental-derived
tissues were cut into small pieces, 1e2 mm3 in size, digested with
10 U/mL collagenase, 2.5 U/mL dispase, and 0.05% TrypsineEDTA
for 90 minutes at 37C. Samples were thoroughly washed three
times with sterile phosphate-buffered saline (PBS). Tissue samples
were then collected in 15 mL tubes and centrifuged at 250 g for
5 minutes. The cell pellet fraction was resuspended in a minimal
essential medium (aMEM; Invitrogen, Waltham, NA, USA) with
10e15% fetal bovine serum (FBS; Invitrogen), 2 mM L-glutamine,
1 ng/mL basic ﬁbroblast growth factor (FGF; Peprotech, Rocky Hill,
NJ, USA), and PSF (100 U/mL penicillin, 100 mg/mL streptomycin,
0.25 mg/mL Fungizone; Invitrogen), then plated in T75 ﬂasks.
Cultures werewashed from three to ﬁve times with PBS after 7 days
to remove nonadherent cells from plastic-adherent colonies, which
were further cultured up to 2 weeks with medium change every
3 days. The culture was maintained in aMEM supplemented with
10e15% FBS, 2 mM L-glutamine, 1 ng/mL basic FGF, and PSF at 37C
with saturated humidity and 5% CO2. Cells were passaged at
approximately 70e90% conﬂuence. The stem cells were sub-
cultured by treating with TrypLE (Life Technologies, Carlsbad, CA,
USA) for 1 minute at 37C. The cells were washed and harvested by
centrifugation at 300 g for 5 minutes, then replated at a lower
density (5000 cells/cm2). The stem cells were maintained in aMEM
supplemented with 10% FBS, 2 mM L-glutamine, 1 ng/mL basic FGF
at 37C in saturating humidity and 5% CO2. MSCs were character-
ized by analyzing the expression of CDmarkers (CD44, CD73, CD90,
CD105, CD11 b, CD19, CD34, CD45, and HLA-DR; BD Stemﬂow hMSC
Analysis Kit; BD Biosciences, San Jose, CA, USA) using ﬂow cytom-
etry. The capability of trilineage differentiation (osteocyte, chon-
drocyte, and adipocyte) were also examined and demonstrated
positive results (data not shown).
Sample preparations for liquid chromatography-tandem mass
spectrometry
Brieﬂy, the MSC pellet was suspended in radioimmunopre-cipi-
tation assay buffer (with 0.25 M sucrose and 0.1 M EDTA, ﬁnal
concentration) at pH 7e8, and then homogenized at 4C using a
Tissue-Tearor homogenizer (Micro-Grinder, RPI Corp, IL USA). Cell
extracts were centrifuged at 1000g for 10 minutes at 4C, and then
the supernatant was centrifuged at 100,000g for an additional
60 minutes at 4C. The supernatant fraction (containing the nuclear
and cytoplasmic fractions) was saved for in-gel digestion. The crude
membrane fraction pellet was resuspended in 6Murea, 5mMEDTA,
and 2% (w/v) sodium dodecyl sulfate for a separate in-gel digestion.
After trypsinization, samples were further processed for liquid
chromatography-tandem mass spectrometry (LC-MS/MS).
Immunophenotypic characterization of placenta-derived MSCs and
ﬁbroblasts
Full-term placentas were collected andMSCs were isolated from
amniotic membrane (AM), chorionic disk (CD), chorionic mem-
brane (CM), and umbilical cord (UC). Placenta-derived cells were
cultured, expanded, and maintained in aMEM with FBS and basic
FGF at 37C and at saturating humidity and 5% CO2. Cells were
subcultured at 80% conﬂuence, and then phenotypically character-
ized by ﬂow cytometry. Immunostaining was performed by incu-
bating cells with the speciﬁed antibodies according tomanufacturer
instructions (BD Stemﬂow hMSC Analysis Kit; BD Biosciences).
Nonspeciﬁc immunoglobulin G of the corresponding class served as
the negative control. Cell suspensions were subjected to ﬂow
cytometry (BD Biosciences FACSCanto II) and data analysis per-
formed using Flowjo 7.6.1 software (http://www.ﬂojo.com).Sorting EphA2-enriched MSCs by magnetic-activated cell sorting or
using a cell sorter
The magnetic-activated cell sorting (MACS) method allows cells
to be separated by incubating with magnetic nanoparticles coated
with antibodies against EphA2-surface antigen. Primary cultures of
placenta-derived MSCs were incubated with the ﬂuorescence-
conjugated anti-human antibodies against EphA2 and sorted with
R-Phycoerythrin (PE) Magnetic Particles according to manufacturer
instructions (MACS Technology, MiltenyiBiotec, Bergisch Gladbach,
Germany). For sorting by cell sorter, cells derived from placentas
were harvested and sorted by anti-EphA2 antibodies using the JAZZ
cell sorter (BD Biosciences) at P0.
Quantitative real-time polymerase chain reaction evaluation of
EphA2 transcript in placenta-derived MSCs and ﬁbroblasts
Total RNA was isolated from 64 populations of placenta-
derived cells (n ¼ 8, including passage 1 and passage 3, from
AM, CD, CM, and UC samples, as well as from Human Foreskin
Fibroblasts (neonatal, PC501A-HFF; System Biosciences, Mountain
View, CA, USA) using the Direct-zolminiprep Kit (Zymo Research
Corporation, Irvine, CA, USA). Complementary DNA (cDNA) was
synthesized with the Transcriptor First Strand cDNA Synthesis Kit
(Roche, Basel, Switzerland) from 100 ng total RNA. Quantitative
real-time polymerase chain reaction (qRT-PCR) was performed
using the Roche Universal Probe Library System with a
LightCycler480 II (Roche) according to manufacturer instructions
using the EphA2 50 primer sequence ACC CCC ACA CAT ATG
AGG AC and the 30 primer sequence TGG ATG GAT CTC GGT
AGT GA.
EphA2 knockdown by lentiviral transduction
Lentiviral transduction was used for shRNA-mediated knock-
down of EphA2 in order to evaluate the role of EphA2 in MSCs.
Each construct had an enhanced green ﬂuorescent protein (EGFP)
reporter to monitor transduction efﬁciency. Four different shRNA
sequences (Target #1, GCGTCATCTCCAAATACAA; Target #2,
GGCTGAGCGTATCTTCATT; Target #3, GCGCCTGTTCACCAAGATT;
and Target #4, GCAGCAAGGTGCACGAATT) were tested, each with
three different multiplicity of infection values (2, 5, and 10), with
each experimental condition was performed in triplicate.
Knockdown efﬁciency was evaluated by qRT-PCR. The best
knockdown efﬁciency achieved was 50%. The clone which
conferred the best knockdown efﬁciency was used in all subse-
quent experiments.
Trans-well migration analysis of EphA2-knockdown MSCs
MSCs transduced with the wild-type, sh-scramble, and sh-
EphA2 knockdown constructs were plated in 8 mm trans-wells at
a density of 30,000 cells/well. FBS (0.2%) and TNF-a were added in
the lower chamber to stimulate migration of MSCs. After 6 hours,
the number of viable migrated cells was determined using Cell
Titer-Glo Luminescent reagents (Promega, Madison, WI, USA) ac-
cording to manufacturer instructions.
Trans-well migration analysis of EphA2high MSCs
Primary cultures of placenta-derived cells were incubated with
magnetic beads conjugated to anti-human antibodies against
EphA2, and then sorted by positive selection. Flow cytometry
analysis was used to conﬁrm the EphA2þ and EphA2 MSC cell
populations after MACS sorting. Cells were plated in 8 mm trans-
Table 2
The immunophenotypic characterization of EphA2-sorted placenta-derived MSCs at
P0 (percentage of positive cells following ﬂow cytometry).
Cell population Cell surface markersa
CD73 CD90 CD105 EphA2
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added in the lower chamber to activate migration of MSCs. After
6 hours, the number of viable migrated cells was determined using
Cell Titer-Glo Luminescent reagents (Promega) according to the
manufacturer's instructions.D17CDP0_unsorted 99.7 95.7 92.1 45.0
D17CDP0_EphA2-sorted 100.0 97.2 98.0 96.6
CD ¼ chorionic disk; D ¼ donor; MSC ¼ mesenchymal stem cell; P ¼ passage.
a The immunophenotypic characterization of the EphA2-sorted MSCs is demon-
strated in MSCs derived from the CD of donor #17 at P0. The results show that
EphA2-positive cells are also CD73 positive, CD90 positive, and CD105 positive.Statistical analyses
A Student t test or two-way analysis of variance was used to
calculate signiﬁcance. A p value < 0.05 was considered statistically
signiﬁcant.Results
Immunophenotypic characterization of placenta-derived MSCs and
ﬁbroblasts
MSCs were derived from AM, CD, CM, and UC. The phenotypic
features of human placenta-derived MSCs were compared with
those of normal human dermal ﬁbroblasts using differential pro-
teomics. This approach employed protein extraction coupled with
gel separation, followed by LC-MS/MS to analyze the membrane
proteome of human placenta-derived MSCs. These data were
compared to the results derived from ﬁbroblasts. EphA2 was
signiﬁcantly upregulated in placenta-derived MSCs as compared to
ﬁbroblasts. The expression levels of EphA2 in ﬁbroblasts were
below the limit of detection sensitivity of the LTQ-Orbitrap XL
instrument.
We assessed the expression of CD11b, CD19, CD34, CD45, CD73,
CD90, CD105, HLA-DR, and EphA2 using ﬂow cytometry. MSCs
isolated from different placenta locations were positive for CD73,
CD90, CD105, and EphA2, and negative for CD11b, CD19, CD34,
CD45, and HLA-DR. Flow cytometry analysis showed that ﬁbro-
blasts were positive for CD73, CD90, CD105, negative for CD11b,
CD19, CD34, CD45, HLA-DR, and negative or had low expression of
EphA2. Placenta-derived MSCs consistently had a high percentage
of EphA2-positive cells, whereas ﬁbroblasts did not. The results are
shown in Table 1.Table 1
Immunophenotypes of placenta-derived mesenchymal stem cells and ﬁbroblasts
(percentage of positive cells following ﬂow cytometry).
Donor/tissue Cell surface markers
CD73 CD90 CD105 EphA2 Negative cocktaila
D12AM 99.6 99.6 75.9 80.0 0.6
D12CD 99.3 99.5 97.0 72.9 0.5
D12CM 99.3 98.0 98.0 77.7 2.3
D12UC 99.4 99.7 90.6 80.2 0.7
D17AM 99.7 95.7 89.4 62.7 0.6
D17CD 99.7 95.7 92.1 45.0 0.6
D17CM 99.6 77.8 88.2 80.7 1.0
D17UC 99.6 99.8 84.9 65.9 1.4
Fibroblasts 99.3 97.7 75.6 18.6 0.6
AM ¼ amniotic membrane; CD ¼ chorionic disk; CM ¼ chorionic membrane;
D ¼ donor; MSC ¼ mesenchymal stem cell; P ¼ passage; UC ¼ umbilical cord.
a Negative Cocktail included the antibodies against CD11b, CD19, CD34, CD45,
and HLA-DR (Human MSC Analysis Kit, BD Stemﬂow, catalog number 562245; BD
Biosciences San Jose, CA, USA). The immunophenotypes of placenta-derived MSCs
were derived from samples from donors #12 and #17 at P0. Flow cytometry analysis
reveals that theMSC populations are ~99.3e99.7% CD73 positive, ~77.8e99.8% CD90
positive, ~75.9e98.0% CD105 positive, and ~45.0e80.7% EphA2 positive at P0. By
contrast, hematopoietic cell lineage-speciﬁc markers, such as CD11b, CD19, CD34,
CD45, and HLA-DR are not expressed in MSCs. Flow cytometry analysis reveals that
ﬁbroblast populations are 99.3% CD73 positive, 97.7% CD90 positive, 75.6% CD105
positive, and 18.6% EphA2 positive. Hematopoietic cell lineage-speciﬁc markers,
such as CD11b, CD19, CD34, CD45, and HLA-DR, are not expressed in ﬁbroblasts.Immunophenotypic characterization of EphA2-sorted placenta-
derived MSCs
Flow cytometry analysis of EphA2-enriched MSCs by MACS
Flow cytometry analysis of MACS-sorted MSCs at P0 revealed a
homogenous cell population in 100% of CD73-positive, ~97.2e99.5%
of CD90-positive, ~96.0e~99.9% of CD105-positive, and
~96.6e100% of EphA2-positive cells since P0 (Table 2). This sug-
gested that EphA2 sorting using antibody-conjugated magnetic
beads could dramatically improve the MSC purity from P0. The
enriched EphA2-positive MSC population could be maintained and
expanded in vitro (Table 3).Flow cytometry analysis of EphA2-enriched MSCs sorted by ﬂow
cytometry cell sorter
Flow cytometry analysis of EphA2-sorted MSCs obtained using
the ﬂow cytometry cell sorter revealed that there were ~99.5e100%
CD73-and CD90-double-positive, ~99.6e100% CD105-and CD90-
double-positive, ~99.5e100% EphA2-and CD90-double-positive,
~99.8e100% CD73-and EphA2-double-positive, ~99.5e100%
CD105-and EphA2-double-positive, and ~99.7e100% CD73-and
CD105-double-positive populations in passages ~2e6 (Table 4).
Our data showed that the EphA2 protein was continuously
expressed and maintained in MSC cultures even at later passages.qRT-PCR evaluation of EphA2 transcripts in placenta-derived MSCs
and ﬁbroblasts
We used qRT-PCR to evaluate EphA2 expression in placenta-
derived multipotent MSCs and compared it with that in ﬁbro-
blasts. Gene expression was normalized to the expression of glyc-
eraldehyde-3-phosphate dehydrogenase in the different cell
populations. The expression of EphA2 transcripts in MSCs was
calculated by fold enrichment compared to the expression of EphA2Table 3
The immunophenotypic characterization of the EphA2-MACS-enriched population
during in vitro expansion (percentage of positive cells following ﬂow cytometry).
Cell population Cell surface markersa
CD73 CD90 CD105 EphA2
D17CDP0_EphA2-sorted 100.0 97.2 98.0 96.6
D17CD_EphA2þ_P1 100.0 99.5 99.9 100.0
D17CD_EphA2þ_P2 100.0 99.3 99.9 99.9
D17CD_EphA2þ_P3 100.0 99.5 99.9 100.0
CD ¼ chorionic disk; D ¼ donor; MACS ¼ magnetic-activated cell sorting;
MSC ¼ mesenchymal stem cell; P ¼ passage.
a The immunophenotypic characterization of the EphA2-sorted MSCs in later
passages. Immunophenotype is demonstrated in the MSCs derived from CD from
donor #17. MSCs were sorted by EphA2-antibody-conjugated magnetic beads at P0
and maintained in optimized MSC culture conditions during in vitro expansion. The
results show that expression of cell-surface marker EphA2 was maintained in later
passages in optimized MSC culture conditions.
Table 4
The immunophenotypic characterization of EphA2-FACS-enriched MSC population during in vitro expansion.a
% CD73þCD90þ CD105þCD90þ EphA2þCD90þ CD73þEphA2þ CD105þEphA2þ CD73þCD105þ
P2 100 100 99.5 100 99.8 99.7
P3 99.5 99.6 99.5 99.8 99.5 99.7
P4 99.9 99.7 99.9 100 99.6 99.7
P6 100 99.9 100 99.9 100 100
D ¼ donor; FACS ¼ ﬂuorescence-activated cell sorting; MSC ¼ mesenchymal stem cell; P ¼ passage; UC ¼ umbilical cord.
a The immunophenotypic characterization of the EphA2-enriched MSCs during later expansion. Immunophenotype is determined in MSCs derived from the UC from donor
#7. MSCs at P0 were sorted by anti-EphA2 antibodies using the cell sorter, and then maintained in optimized MSC culture conditions during later passages. The expression of
the EphA2 cell-surface marker was preserved in later passages.
Figure 1. Real-time polymerase chain reaction quantitation of EphA2 mRNA. EphA2
mRNA levels in placenta-derived MSCs were evaluated by fold enrichment compared
to the expression of EphA2 in ﬁbroblasts, i.e., by comparison of EphA2 mRNA levels in
MSCs to EphA2 mRNA levels in ﬁbroblasts (MSCs/ﬁbroblasts). MSC samples from do-
nors #12, #17, #21, and #28 were used to determine EphA2 transcript levels. The re-
sults show that EphA2 is highly enriched in MSCs compared to ﬁbroblasts.
AM ¼ amniotic membrane; BS ¼ fetal bovine serum; CD ¼ chorionic disk;
CM ¼ chorionic membrane; D ¼ donor; MSC ¼mesenchymal stem cell; P1 ¼ passage1;
P3 ¼ passage3; UC ¼ umbilical cord.
Figure 2. Flow cytometry analysis of mixed populations of MSCs and ﬁbroblasts. MSCs
derived from the UC from donor #23 were mixed with ﬁbroblasts at different ratios.
The percentage of EphA2þ detected by ﬂow cytometry decreased proportionally in
response to the increased ﬁbroblast population. FB ¼ ﬁbroblasts; MSC ¼mesenchymal
stem cell; UC ¼ umbilical cord.
S.-P. Shen et al. / Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 749e756 753in ﬁbroblasts. The results showed that EphA2 was highly expressed
in MSCs as compared to ﬁbroblasts (Figure 1).
Flow cytometry analysis of mixed populations of MSCs and
ﬁbroblasts
In order to evaluate the feasibility of using EphA2 as a biomarker
to separate placenta-derived MSCs from ﬁbroblasts, MSCs derived
from the UC of donor #23 were mixed with ﬁbroblasts in the
following ratios (MSC:ﬁbroblasts in cell numbers): 2  105:0,
2  105:2  104, 2  105:4  104, 2  105:2  105, 2  105:1  106,
2 105:2 106, and 0:2 105 (Figure 2). The EphA2þ population in
each sample was determined using ﬂow cytometry. We showed
that the EphA2þ population decreased in proportion to the increase
in the ﬁbroblast population.
The response of MSCs to TNF-a signaling was compromised by
EphA2 knockdown
shRNA-mediated EphA2 knockdown vectors (shEphA2) were
used to evaluate the functions of EphA2 in MSCs. Each lentiviral
construct had an EGFP reporter to monitor transduction efﬁciencyFigure 3. EphA2 RNA levels were evaluated by qRT-PCR. Total RNA expression levels in
different individual cell populations were normalized to endogenous GAPDH expres-
sion levels. “Scramble” represents a scrambled control in the shRNA knockdown
experiment. EphA2 mRNA levels in knockdown samples are compared to levels in
normal wild-type UC-derived MSCs. qRT-PCR results conﬁrm the sh-EphA2 knock-
down efﬁciency. D ¼ donor; MSC ¼ mesenchymal stem cell; qRT-PCR ¼ quantitative
real-time polymerase chain reaction; UC ¼ umbilical cord.
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knockdown efﬁciency was achieved (Figure 3).
At injury sites, MSCs can be induced and mobilized to exert
immunoregulatory effects in response toTNF-a and IFN-g [32]. MSCs
exert their immunosuppressive functionality by suppressing T- and
B-cell responses following activation by various cytokines [32]. In
inﬂammatory joint diseases, such as rheumatoid arthritis, MSCs in
the bone marrow migrate to the joints via a TNF-a-dependent
mechanism andmay be partially responsible for the disease process
[33]. Increased numbers of MSCs have also been demonstrated in
periarticular tissues in osteoarthritis, which may reﬂect an attempt
at joint repair or regeneration following injury [19]. It was proposed
that TNF-a release in an inﬂammatory environment confers
immunosuppressive properties upon MSCs when TNF-a binds to
TNF-R1 of MSCs and activates the NF-kB pathway [34]. Here, we
investigated the role of EphA2 in MSCs in response to inﬂammatory
stimuli, such as TNF-a signaling, and determined if EphA2 was
involved inMSCmigration during inﬂammation [2,35]. The mobility
of EphA2high and EphA2low MSCs under basal culture conditions or
in the presence of TNF-a inﬂammatory stimuli was examined.
Trans-well migration analysis of EphA2-knockdown MSCs
The wild-type, sh-scramble, and sh-EphA2-targeted MSCs were
plated in 8 mm trans-wells at a density of 30,000 cells/well. FBS
(0.2%) and TNF-a were added into the lower chamber to activate
migration of MSCs. The data revealed that EphA2 knockdown
compromised the ability of MSCs to migrate, as well as to respond
to TNF-a signaling (Figure 4).
Trans-well migration analysis of EphA2high MSCs
Primary cultures of placenta-derived cells were incubated with
magnetic beads conjugated to anti-human antibodies against
EphA2. Cells were then sorted by positive selection. Flow cytometry
analysis conﬁrmed the presence of EphA2þ (or EphA2high) MSCs
and EphA2 (or EphA2low) cell populations after MACS. Cells were
plated in 8 mm trans-wells at a density of 30,000 cells/well. FBS
(0.2%) and TNF-a were added in the lower chamber to activate
migration of MSCs. The data revealed that the EphA2high MSC
population had an enhanced capability to respond to TNF-a signal
and to migrate (Figure 4).
The migration of MSCs was signiﬁcantly affected by the addition
of TNF-a to the basal medium (Figures 4A and 4B). Addition of TNF-
a to the basal medium increased MSC migration in a TNF-a-dose-
dependent manner (see Figure 4A). By contrast, the mobility of
EphA2-knockdown MSCs, as well as EphA2 cells, was abolished.
The effect of EphA2 on the migration of MSCs in response to TNF-a
was more obvious when the luminescent signal was converted to
migrated cell population relative tomigrated wild-typeMSCs in the
0.2% FBS control in fold change (Figure 4B).
Discussion
MSCs derived from different sources display similar phenotypic
and functional characteristics in vitro [30]. However, tissue-origin-
speciﬁc differences are also apparent, making the deﬁnition of a
progenitor cell challenging [30]. Previously, Ann E. Canﬁeld's group
[30] combined enrichment of cell-matrix interface proteins with
quantitative MS and identiﬁed a panel of signature proteins thatFigure 4. Trans-well migration assay and detection of cell viability. Cells were plated in 8 mm
lower chamber to stimulate the migration of MSCs. After 6 hours, the number of viable migr
capability of sh-EphA2 MSCs to respond to TNF-a signaling. The capability to respond to TNF
(A) Viable migrated cells are presented as signal intensity. (B) Viable migrated cells are p
FBS ¼ fetal bovine serum; MSC ¼ mesenchymal stem cell; RLU ¼ relative light unit.were signiﬁcantly enriched in bone-marrow-derived MSC and
HUCPVC cultures as compared with differentiated mesenchymal
cells [adult human dermal ﬁbroblasts (HDFs)]. Comparing bone
marrow MSCs or HUCPVCs against HDF preparations identiﬁed
proteins in membrane-enriched andmatrix-enriched fractions that
were signiﬁcantly increased in all adult MSCs and HUCPVCs versus
HDFs. Proteins identiﬁed as enriched in bone marrow MSCs and
HUCPVCs comprised known MSC markers CD106, CD49c, and
CD58, and novel markers, including EphA2 [30]. In this approach,
multiple sources of MSCs, except HUCPVCs, were derived from
adult tissues. The differentiatedmesenchymal cells used as internal
controls were derived from adult HDFs.
In our study, in contrast to the materials derived from adult
tissues, we isolated MSCs from fetal-originated tissues from
placenta, including AM, CM, CD, and Wharton's jelly within the UC.
Characterization of differential proteomics data from fetal-
originated MSCs (from AM, CM, CD, and UC) compared to human
fetal ﬁbroblasts led to the identiﬁcation of EphA2 as a surface-
protein marker that could discriminate placental and UC MSCs
from ﬁbroblasts during the isolation process.
Human MSCs have been isolated from a wide range of tissues
using different techniques. The heterogeneity of the cell population
with the different techniques used to isolate, culture, and deﬁne
MSCs often led to experimental variability and contradictory data.
The molecular expressions seemed to vary depending on the tissue
source and culture conditions. The debate over the use of a certain
surface antigen as a marker to deﬁne MSCs implied the difﬁculty to
identify markers independent from the MSC tissue source and
culture conditions. According to the data published by Canﬁeld et al
[30] and the results from our study, EphA2 was highly expressed in
different populations of MSCs derived from fetal, as well as from
adult tissues, regardless of the culture conditions. Hence, wewould
like to propose that the EphA2 protein could serve as an additional
universal biomarker to increase the conﬁdence in isolated MSC
identiﬁcation and veriﬁcation.
One of the therapeutic attributes of MSCs is their ability to
mobilize to sites of injury where they participate in repair [32].
Canﬁeld et al [30] used a wound assay to investigate whether
cellular migration was affected after knockdown of EphA2 expres-
sion. A small, but statistically signiﬁcant decrease in migration was
detected following EphA2 siRNA treatment [30]. We observed
similar patterns in our trans-well migration assay (Figure 4).
Recent studies demonstrated that inﬂammatory factors, such as
TNF-a and interleukin-1b, may provide cues to mobilize MSCs to
tissue damage sites [32]. Tissue injury is associated with the acti-
vation of inﬂammatory cells. Inﬂammatory mediators, such as TNF-
a, interleukin-1b, free radicals, chemokines, and leukotrienes, are
often produced by phagocytes in response to damaged cells and
leaked cell contents [32]. These inﬂammatory molecules and im-
mune cells, together with endothelial cells and ﬁbroblasts,
orchestrate changes in the microenvironment that result in the
mobilization of MSCs to damaged tissue [32]. Once MSCs have
entered the microenvironment of injured tissues, signals from the
microenvironment could stimulate the release of an array of cyto-
kines or growth factors by MSCs. These secreted factors modulate
the immune response at the damaged site, and promote the
development of ﬁbroblasts, endothelial cells, and tissue progenitor
cells, carrying out tissue regeneration and repair [32].trans-wells at a density of 30,000 cells/well. FBS (0.2%) and TNF-awere added into the
ated cells was determined. The data revealed that EphA2 knockdown compromises the
-a signaling and migration of MSCs is enhanced in EphA2-enriched populations of cells.
resented as a relative proportion compared to wild-type MSCs in 0.2% FBS control.
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to mimic the migratory response of MSCs to inﬂammatory factor
TNF-a. MSCs were plated and cultured in the trans-well inserts
with basal media, and FBS (0.2%) and TNF-a were added in the
lower chamber to create an attractant gradient to stimulate
migration of MSCs. The capacity of MSC motility toward inﬂam-
matory factor TNF-a could be measured and quantiﬁed by the
number of migrated cells using a homogeneous method of deter-
mining the number of viable cells based on quantitation of the
adenosine triphosphate present (an indicator of metabolically
active cells). We applied a lentiviral transduction system to
knockdown EphA2 expression in MSCs to investigate whether
cellular migration toward TNF-a was affected after knockdown of
EphA2 expression.
Our results showed that addition of TNF-a to the basal medium
in the lower chamber increased MSC migration in a TNF-a-dose-
dependent manner (Figure 4). The data revealed that EphA2
knockdown signiﬁcantly affected the migratory ability of MSCs
(~40% decrease), as well as response to TNF-a signaling (Figure 4).
By contrast, the EphA2high MSC population after sorting exhibited
an enhanced migratory capability and response to TNF-a signaling
(Figure 4). We concluded that the EphA2 protein plays a crucial role
not only in MSC migration, but also migration in response to in-
ﬂammatory factor TNF-a.
In summary, our present study reported a method of isolation of
placenta-derivedMSCswith high homogeneity and at early passage
in primary cultures. Using a proteomics proﬁling approach, we
identiﬁed a surface biomarker, EphA2, enriched in placenta-derived
MSCs. This protein could be used to separate fetal-originated
placental MSCs from ﬁbroblasts during the process of isolation.
The present study demonstrated that cell sorting using the EphA2
surface marker could distinguish and purify MSCs in a primary
culture of cells derived from placenta-related tissues. Expression of
EphA2 was stable during the in vitro expansion process. The EphA2
protein plays a crucial role in MSC migration. EphA2-sorted MSCs
exhibited superior responsiveness to TNF-a signaling in an in-
ﬂammatory environment, and showed enhanced mobility, as
compared with unsorted MSCs. By contrast, the mobility of MSCs
and mobility in response to TNF-a were severely compromised in
EphA2-knockdown MSCs, as well as EphA2 cells. However, the
exploration of in vitro functional assays of MSCs was still limited in
this study. A broader range of functional analyses is essential to
further deﬁne the function of EphA2 in MSC biology.Conﬂicts of interest
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